Business Context and Reporting Period
This Form 6-K filing by Can-Fite Biopharma Ltd. covers the period of January 2023, with a specific announcement date of January 13, 2023. The filing serves to notify shareholders of an upcoming Special General Meeting of Shareholders scheduled for February 21, 2023, at 3:00 p.m. Israel time at the company's offices in Petach Tikva, Israel.
Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This document is a procedural notice regarding a shareholder meeting and does not contain financial statements or performance data.
Material Changes
No material changes to financial performance or operations are reported in this filing. The primary event is the scheduling of a corporate governance meeting.
Guidance, Outlook, and Management Commentary
Management has announced the convening of a Special General Meeting to vote on a proposal described in the attached Notice and Proxy Statement (Exhibit 99.1). The filing includes forms for voting by proxy for both ordinary share holders and American Depositary Share holders. No specific business outlook, risk factors, or unusual items are detailed in the body of this report.
Key Facts for Investor Verification
- Verify the specific proposal to be voted upon in the attached Notice and Proxy Statement (Exhibit 99.1), as the summary text does not detail the subject matter.
- Confirm the record date for shareholder eligibility, which is not stated in this filing text.
- Review the voting procedures for both ordinary shares and American Depositary Shares as outlined in the attached exhibits.
- Note that this filing incorporates by reference into various Registration Statements (Forms S-8 and F-3).